New federal funding spurs research on cancer therapies
A new diagnostic test to determine whether cancer patients should respond well to a specific targeted drug therapy is the goal of a project awarded funding today from Genome Canada. The $3.3-million project, co-led by Christoph Borchers, a University of Victoria biochemist and director of the UVic-Genome BC Proteomics Centre, is a collaboration between UVic, the Jewish General Hospital – Segal Centre in Montreal and industrial partners AstraZeneca and MRM Proteomics.
For more information:
--30--